Clinical Research Directory
Browse clinical research sites, groups, and studies.
Glycemic Impact of NNS Via the Gut Microbiome
Sponsor: Tufts University
Summary
This pilot study will evaluate the feasibility and acceptability of a 30-day sucralose intervention among adults with prediabetes. Participants will consume six commercial sucralose (Splenda®) packets daily for 30 days while wearing a blinded continuous glucose monitor (CGM). Oral glucose tolerance tests (OGTTs) with blood draws will be performed at baseline and after 30 days to assess glucose incremental area under the curve (iAUC). Stool samples will also be collected to assess the feasibility of microbiome sample collection for future studies. The study will generate preliminary data to inform the design of a larger randomized clinical trial examining the effects of non-nutritive sweeteners on glucose homeostasis and the gut microbiome.
Official title: Non-Nutritive Sweeteners, Glucose Homeostasis, and the Gut Microbiome in Prediabetes
Key Details
Gender
All
Age Range
35 Years - Any
Study Type
INTERVENTIONAL
Enrollment
10
Start Date
2026-10
Completion Date
2027-07
Last Updated
2026-10-09
Healthy Volunteers
No
Conditions
Interventions
Sucralose
Sucralose (Splenda®): six commercial tabletop packets daily, totaling 72 mg sucralose per day, for 30 days.
Locations (1)
Tufts Medical Center
Boston, Massachusetts, United States